<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01905943</url>
  </required_header>
  <id_info>
    <org_study_id>MO28543</org_study_id>
    <secondary_id>2013-000087-29</secondary_id>
    <nct_id>NCT01905943</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Multicenter, Open-Label, Single-Arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter, open-label, single-arm study will evaluate the safety and efficacy of
      obinutuzumab alone or in combination with chemotherapy in participants with previously
      untreated or relapsed/refractory chronic lymphocytic leukemia (CLL). This is a
      Post-Authorization Safety Study. Participants will receive 6 cycles of single-agent
      obinutuzumab or obinutuzumab in combination with chemotherapy at the investigator's
      discretion. Each participant will be followed until 30 months after the last participant has
      been enrolled. Total length of the study is anticipated to be approximately 5 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 4, 2013</start_date>
  <completion_date type="Actual">October 8, 2018</completion_date>
  <primary_completion_date type="Actual">December 29, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>Baseline up to time of primary completion (3 years)</time_frame>
    <description>An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs, including AEs of Special Interest and AEs of Particular Interest, were reported based on the national cancer institute common terminology criteria for AEs, Version 4.0 (NCI-CTCAE, v4.0). Reported are the number of subjects with AEs, Grade 3-5 AEs, and Serious Adverse Events (SAEs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events of Special Interest (AESIs)</measure>
    <time_frame>Baseline up to time of primary completion (3 years)</time_frame>
    <description>The following AEs were defined as AESIs: AEs with the preferred term Tumour Lysis Syndrome (TLS), Infusion-Related Reactions (IRRs) defined as AEs that occurred during or within 24 hours of the completion of obinutuzumab infusion and were assessed as related to obinutuzumab by the Investigator, Infections defined as AEs from System Organ Class (SOC) &quot;Infections and infestations&quot; and AEs with the preferred term Neutropenia. Reported are number of participants with total AESIs, IRRs, Infections, Neutropenia and TLS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events of Particular Interest (AEPIs)</measure>
    <time_frame>Baseline up to time of primary completion (3 years)</time_frame>
    <description>The following AEs were defined as AEPIs: AEs with the preferred term Progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation defined as AEs with preferred term containing &quot;Hepatitis B&quot; or &quot;hepatitis acute&quot;, thrombocytopenia defined via Roche MedDRA basket subgroup &quot;haematopoietic thrombocytopenia&quot;, second malignancies defined as AEs from the SOC &quot;Neoplasms benign, malignant and unspecified&quot; starting 6 months after the first study drug intake, second malignancies based on standardised MedDRA queries (SMQ) starting 6 months after the first study drug intake based on the MedDRA SMQ &quot;Malignant or unspecified tumours&quot;, in which benign neoplasms are not included, Cardiac events including AEs from the SOC &quot;Cardiac disorders&quot;, and hemorrhagic events defined via Roche MedDRA basket subgroup &quot;Haemorrhagic events&quot;. Reported are number of participants with total AEPIs and each of the AEPI categories.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Overall Response (OR) at Final Response Assessment (FRA)</measure>
    <time_frame>3 months after the last dose of study treatment (up to approximately 5 years)</time_frame>
    <description>OR: percentage of participants with complete response (CR) or CR with incomplete marrow recovery (CRi), or partial response (PR), as determined by the investigator based on International Workshop on Chronic Lymphocytic Leukemia (IWCLL) tumor response criteria. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils &gt;1,500/mcL, platelets &gt; 100,000/mcL, hemoglobin &gt; 110 g/L and bone marrow normocellular for age. Cri: CR with persistent cytopenia. PR: &gt;/= 50% decrease in peripheral blood lymphocyte count AND &gt;/= 50% reduction in lymphadenopathy OR &gt;/= 50% reduction of liver enlargement OR &gt;/= 50% reduction of spleen PLUS one of the following: neutrophils &gt;1,500/mcL, platelets &gt; 100,000/mcL, hemoglobin &gt; 110 g/L OR &gt;/= 50% increase in neutrophils, platelets or hemoglobin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Minimal Residual Disease (MRD)-Negativity as Assessed by Flow Cytometry</measure>
    <time_frame>3 months after the last dose of study treatment (up to approximately 5 years)</time_frame>
    <description>MRD-negativity was defined as the presence of less than 1 chronic lymphocytic leukemia (CLL) cell per 10,000 leukocytes in blood and bone marrow as assessed by flow cytometry 3 months after last dose of study treatment (i.e. at final response assessment [FRA] visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Best Overall Response (BOR)</measure>
    <time_frame>Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)</time_frame>
    <description>BOR was defined as the percentage of participants with the best response obtained throughout the trial with CR, CRi, or PR, as determined by the investigator based on IWCLL tumor response criteria. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils &gt;1,500/mcL, platelets &gt; 100,000/mcL, hemoglobin &gt; 110 g/L and bone marrow normocellular for age. Cri: CR with persistent cytopenia. PR: &gt;/= 50% decrease in peripheral blood lymphocyte count AND &gt;/= 50% reduction in lymphadenopathy OR &gt;/= 50% reduction of liver enlargement OR &gt;/= 50% reduction of spleen PLUS one of the following: neutrophils &gt;1,500/mcL, platelets &gt; 100,000/mcL, hemoglobin &gt; 110 g/L OR &gt;/= 50% increase in neutrophils, platelets or hemoglobin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Progression-Free Survival (PFS)</measure>
    <time_frame>Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)</time_frame>
    <description>Kaplan Meier estimate of the median PFS was defined as the time at which half of the participants have progressed (progressive disease [PD]) based on IWCLL tumor response criteria or died from any cause, whichever occurred first. PD: at least one of the following: &gt;/= 50% increase in the absolute number of circulating lymphocytes to at least 5,000/mcL, appearance of new palpable lymph nodes, &gt;/= 50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, &gt;/= 50% increase in the enlargement of the liver and/or spleen, transformation to more aggressive histology, progression of any cytopenia, decrease of hemoglobin levels by more than 20 g/L or to less than 100 g/L, decrease of platelet counts by more than 50% or to less than 100,000 /mcL, decrease of neutrophil counts by more than 50% or to less than 1,000/mcL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Response (TTR)</measure>
    <time_frame>Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)</time_frame>
    <description>Kaplan Meier estimate of median TTR was defined as the time at which half of the participants reached CR or PR based on IWCLL tumor response criteria. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils &gt;1,500/mcL, platelets &gt; 100,000/mcL, hemoglobin &gt; 110 g/L and bone marrow normocellular for age. PR: &gt;/= 50% decrease in peripheral blood lymphocyte count AND &gt;/= 50% reduction in lymphadenopathy OR &gt;/= 50% reduction of liver enlargement OR &gt;/= 50% reduction of spleen PLUS one of the following: neutrophils &gt;1,500/mcL, platelets &gt; 100,000/mcL, hemoglobin &gt; 110 g/L OR &gt;/= 50% increase in neutrophils, platelets or hemoglobin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Event-Free Survival (EFS)</measure>
    <time_frame>Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)</time_frame>
    <description>Kaplan Meier estimate of median EFS is the time at which half of the participants have progressed as assessed by investigator based on IWCLL tumor response criteria, or have initiated a non-protocol-specified anti-leukemia therapy or died, whichever occurs first. PD: at least 1 of the following: &gt;/= 50% increase in absolute number of circulating lymphocytes to at least 5,000/mcL, appearance of new palpable lymph nodes, &gt;/= 50% increase in longest diameter of any previous site of clinically significant lymphadenopathy, &gt;/= 50% increase in enlargement of liver and/or spleen, transformation to more aggressive histology, progression of any cytopenia, decrease of hemoglobin levels by more than 20 g/L or to less than 100 g/L, decrease of platelet counts by more than 50% or to less than 100,000 /mcL, decrease of neutrophil counts by more than 50% or to less than 1,000/mcL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Overall Survival (OS)</measure>
    <time_frame>Baseline until death (Approximately up to 5 years)</time_frame>
    <description>Kaplan Meier estimate of median OS was defined as the time at which half of the participants had died, regardless of the cause of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to New Anti-Leukemia Therapy (TTNT)</measure>
    <time_frame>Baseline until end of study (up to approximately 5 years)</time_frame>
    <description>Kaplan Meier estimate of median TTNT was defined as the time at which half of the participants have initiated a new anti-leukemic therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Duration of Response (DoR)</measure>
    <time_frame>Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)</time_frame>
    <description>Kaplan Meier estimate of median DoR was defined as the time at which half of the responding (PR or CR) participants had progressed (PD) or died from any cause, whichever occurred first. PR: &gt;/= 50% decrease in peripheral blood lymphocyte count AND &gt;/= 50% reduction in lymphadenopathy OR &gt;/= 50% reduction of liver enlargement OR &gt;/= 50% reduction of spleen PLUS one of the following: neutrophils &gt;1,500/mcL, platelets &gt; 100,000/mcL, hemoglobin &gt; 110 g/L OR &gt;/= 50% increase in neutrophils, platelets or hemoglobin. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils &gt;1,500/mcL, platelets &gt; 100,000/mcL, hemoglobin &gt; 110 g/L and bone marrow normocellular for age. PD: as defined in the description for Event-Free Survival outcome measure.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">979</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Obinutuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive obinutuzumab either alone as single agent or in combination with chemotherapy (Fludarabine/Cyclophosphamide [FC], Bendamustine or Chlorambucil) at the investigator's discretion. Each cycle is of 28-days duration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Bendamustine: 90 milligram per millilitre square (mg/m^2) IV over 60 minutes once daily (QD) Day 1-2 in participants previously untreated or 70 mg/m^2 I.V. over 60 minutes QD Day 1-2 in participants with relapsed/refractory disease. In non-fit participants only, investigators may opt at their own discretion to use lower initial doses of bendamustine, i.e., bendamustine 70 mg/m^2 in previously untreated participants, and bendamustine 50 mg/m^2 in relapsed/refractory subjects (over 60 minutes qd Day 1-2 for each administration).</description>
    <arm_group_label>Obinutuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorambucil</intervention_name>
    <description>Chlorambucil 0.5 mg/kg p.o. qd on Day 1 and Day 15 in non-fit participants only.</description>
    <arm_group_label>Obinutuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 250 mg/m^2 I.V. over 15-30 minutes qd Day 1-3 or Cyclophosphamide 250 mg/m^2 p.o. QD Day 1-3 in fit participants only.</description>
    <arm_group_label>Obinutuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 25 mg/m^2 I.V. over 30 minutes QD Day 1-3 or Fludarabine 40 mg/m^2 per os (p.o.) QD Day 1-3 in fit participants only.</description>
    <arm_group_label>Obinutuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>Participants will receive obinutuzumab 1000 mg IV infusion on Days 1/2 (dose split over 2 consecutive days; 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1, and on Day 1 of Cycles 2, 3, 4, 5, and 6. Each cycle is of 28-days duration.</description>
    <arm_group_label>Obinutuzumab</arm_group_label>
    <other_name>Gazyva®, RO5072759</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated documented CLL according to National Cancer
             Institute/international workshop on CLL (NCI/iwCLL) criteria OR relapsed and/or
             refractory documented CLL participants requiring treatment according to NCI/iwCLL
             criteria; participants with up to 3 relapses are eligible

          -  Refractory participants if last treatment was with single-agent therapy, single-agent
             chemotherapy, or single-agent antibody

          -  Participants with 17p-deletion and/or p53 mutation may be included at the
             investigator's discretion

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Life expectancy greater than (&gt;) 6 months according to the investigator's opinion

          -  Adequate hematological function

        Exclusion Criteria:

          -  Participants who have received more than 3 previous CLL treatment lines

          -  Documented transformation of CLL to aggressive lymphoma (Richter's transformation)

          -  Participants who are refractory to immunochemotherapy

          -  Participants with abnormal laboratory values

          -  One or more individual organ/system impairment score of 4 as assessed by the
             cumulative illness rating scale (CIRS) definition, excluding the eyes, ears, nose,
             throat and larynx organ systems

          -  Participants with a history of progressive multifocal leukoencephalopathy (PML)

          -  History of severe allergic or anaphylactic reactions to monoclonal antibody therapy

          -  Known hypersensitivity to the study drugs

          -  History of prior malignancy unless the malignancy has been treated with a curative
             intent and in remission without treatment for greater than or equal to (&gt;/=) 5 years
             prior to enrollment and with the exception of curatively-treated basal cell carcinoma,
             squamous cell carcinoma of the skin, low grade in situ carcinoma of the cervix, or low
             grade, early stage localized prostate cancer treated surgically with curative intent

          -  Regular treatment with corticosteroids during the 28 days prior to the start of Cycle
             1, Day 1, unless administered for indications other than CLL at a dose equivalent to
             less than or equal to (&lt;/=) 30 milligrams per day (mg/day) prednisone

          -  Regular treatment with immunosuppressive medications following previous organ
             transplantation

          -  Evidence of significant, uncontrolled concomitant diseases

          -  Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection
             (excluding fungal infections of the nail beds) or a major episode of infection
             requiring treatment with intravenous (IV) antibiotics or hospitalization within 28
             days prior to the start of Cycle 1, Day 1

          -  Vaccination with live vaccines within 28 days prior to start of Cycle 1, Day 1

          -  Major surgery (within 28 days prior to the start of Cycle 1, Day 1), other than for
             diagnosis

          -  Positive for chronic hepatitis B, hepatitis C, human T-lymphotropic virus 1 (HTLV 1)
             or human immunodeficiency virus (HIV) infection

          -  Pregnant or lactating women

          -  Fertile men or women of childbearing potential

          -  Participation in another clinical trial with drug intervention within 28 days prior to
             start of Cycle 1, Day 1 and during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Iturraspe</name>
      <address>
        <city>Santa Fé</city>
        <zip>3000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Erasme; Neurologie</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jessa Zkh (Campus Virga Jesse)</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Sart-Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Augustinus Wilrijk</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Center of the Republic of Srpska, Clinic for Internal Disease, Hematology Dept</name>
      <address>
        <city>Banja Luka</city>
        <zip>88000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Center Sarajevo, Clinic for Hematology</name>
      <address>
        <city>Sarajevo</city>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas - UFRGS</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cancer de Barretos</name>
      <address>
        <city>Barretos</city>
        <state>SP</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Amaral Carvalho</name>
      <address>
        <city>Jau</city>
        <state>SP</state>
        <zip>17210-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Ensino e Pesquisa Sao Lucas - IEP</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01236-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sirio Libanes; Centro de Oncologia</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01308-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Estadual do Servidor Publico; Hematologia</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04029-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas - FMUSP; Hematologia</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Marcelina;Oncologia</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>08270-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional health authority A vitalite health network</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 8X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre; Oncology</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6M2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Lemoyne; Centre Integre de Lutte Contre Le Cancer de La Monteregie</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve- Rosemont; Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de sante et de services sociaux Rimouski Neigette</name>
      <address>
        <city>Rimouski</city>
        <state>Quebec</state>
        <zip>G5L 5T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre; Uni of Saskatoon Campus</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec - Hopital de l'Enfant-Jesus; Unite de Recherche en Hematologie et Oncologie</name>
      <address>
        <city>Quebec</city>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cairo University Hospital Al Kasr El Ainy</name>
      <address>
        <city>Cairo</city>
        <zip>11559</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Cairo</city>
        <zip>11796</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Estonia Regional Hospital; Hematology</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tartu Uni Hospital; Hematology - Oncology Clinic</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <zip>70211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital; Hematology</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku Uni Central Hospital; Dept of Internal Medicine</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu; Medecine D</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Victor Dupouy; Hematologie</name>
      <address>
        <city>Argenteuil</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Augustin Morvan; Hematologie</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cote De Nacre; Hematologie Biologique</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Estaing; Hematologie Clinique Adultes</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor; Hematologie Clinique</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Site Du Bocage;Hematologie Clinique</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Departemental Les Oudairies</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Du Mans; Medecine Hematologie Oncologie</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez; Hematologie</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Uni Ire Dupuytren; Hematologie</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Eloi; Hematologie Oncologie Medicale</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Emile Muller; Hematologie</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Hotel Dieu Et Hme;Hopital De Jour</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis ; Service d Oncologie Medicale Fougere 6 (Pr Misset)</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine; Hematologie Clinique</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere; Hematologie Clinique</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Jean; Hematologie</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital De Haut Leveque; Hematologie Clinique</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Lyon Sud; Hemato Secteur Jules Courmont</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier René Dubos; Hematologie</name>
      <address>
        <city>Pontoise</city>
        <zip>95300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Robert Debre; Hematologie Clinique</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel; Hematologie</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Saint Brieuc - Hôpital Yves Le Foll</name>
      <address>
        <city>St Brieuc</city>
        <zip>22027</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bretonneau; Hematologie Therapie Cellulaire</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämatologisch-onkologische Praxis Dr. med. - Heinrich, - Bangerter</name>
      <address>
        <city>Augsburg</city>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis; Prof. Dr. Michael Kiehl und Dr.med. Wolfgang Stein</name>
      <address>
        <city>Frankfurt an der Oder</city>
        <zip>15236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologisches Zentrum am Bethanien-Kankenhaus</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dres.Andreas Ammon und Dirk Meyer</name>
      <address>
        <city>Göttingen</city>
        <zip>37073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OncoResearch Lerchenfeld GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Gemeinschaftspraxis</name>
      <address>
        <city>Magdeburg</city>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Ostalb, Stauferklinikum Schwäbisch-Gmünd; Zentrum für Innere Medizin</name>
      <address>
        <city>Mutlangen</city>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dres. Hans-Dieter Schick Dorothea Schick Burkhard Schmidt u.w.</name>
      <address>
        <city>München</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. med. Holger Klaproth / Dr. med. Anca Astrid Cura</name>
      <address>
        <city>Neunkirchen/Saar</city>
        <zip>66538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>eps - early phase GmbH</name>
      <address>
        <city>Pößneck</city>
        <zip>07381</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologianova GmbH - Gesellschaft für Innovationen in der Onkologie</name>
      <address>
        <city>Recklinghausen</city>
        <zip>45659</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis &amp; Tagesklinik f. Hämatologie &amp; Onkologie Regensdorf / Schwandorf / Wörth</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo.</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Dres. Rudolf Schlag und Björn Schöttker</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens Evangelismos; Hematology</name>
      <address>
        <city>Athens</city>
        <zip>106 76</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laiko General Hospital of Athens; A Propedeutical Clinic of Internal Medicine</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laiko General Hospital; Hematology Clinic</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Ioannina; Hematology</name>
      <address>
        <city>Ioannina</city>
        <zip>455 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgios Papanikolaou Hospital; Hematology Department</name>
      <address>
        <city>Thessaloniki</city>
        <zip>570 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae Uni Hospital; Oncology</name>
      <address>
        <city>Dublin</city>
        <zip>7</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Limerick - Oncology</name>
      <address>
        <city>Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waterford Regional Hospital; Department Of Medical Oncology</name>
      <address>
        <city>Waterford</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center; Hematology Deptartment</name>
      <address>
        <city>Beer Sheva</city>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bnei-Zion Medical Center; Hematology Dept</name>
      <address>
        <city>Haifa</city>
        <zip>3339419</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Karem Hospital; Haematology</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <zip>7610001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ichilov Sourasky Medical Center; Heamatology</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osp. Pugliese; Divisione de Ematologia</name>
      <address>
        <city>Catanzaro</city>
        <state>Calabria</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cardarelli; Divisione Di Ematologia</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale S. Anna; Sezione Di Ematologia</name>
      <address>
        <city>Ferrara</city>
        <state>Emilia-Romagna</state>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica</name>
      <address>
        <city>Meldola</city>
        <state>Emilia-Romagna</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Policlinico Di Modena; Ematologia</name>
      <address>
        <city>Modena</city>
        <state>Emilia-Romagna</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AUSL di Piacenza - Ospedale &quot;Guglielmo da Saliceto&quot;;U.O. Ematologia</name>
      <address>
        <city>Piacenza</city>
        <state>Emilia-Romagna</state>
        <zip>29121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osp. S. Maria Delle Croci; U.O. Di Ematologia</name>
      <address>
        <city>Ravenna</city>
        <state>Emilia-Romagna</state>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Infermi Di Rimini; Unità Operativa di Oncologia e Oncoematologia</name>
      <address>
        <city>Rimini</city>
        <state>Emilia-Romagna</state>
        <zip>47900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita' Degli Studi La Sapienza-Ist.Di Ematologia; Dip Biot Cel e Ematol</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uni Degli Studi Di Genova; 1A Divisione Di Ematologia</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore Di Milano; U.O. Ematologia I - Padiglione Marcora</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST GRANDE OSPEDALE METROPOLITANO NIGUARDA; Struttura Complessa di Ematologia</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Piemonte Est Amedeo Avogadro; Div.Ematologia- Dip.Clinica Med.Sperim.&amp; Ircad</name>
      <address>
        <city>Novara</city>
        <state>Piemonte</state>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Molinette - Universita' Di Torino; Cliniche Universitarie Ematologia I</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliera oo rr di foggi; Hematology</name>
      <address>
        <city>Foggia</city>
        <state>Puglia</state>
        <zip>71100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Vito Fazzi; Div. Oncoematologia</name>
      <address>
        <city>Lecce</city>
        <state>Puglia</state>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Oncologico A Businco-Cagliari; Ematologia Sez.</name>
      <address>
        <city>Cagliari</city>
        <state>Sardegna</state>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda USL 6 Livorno - P.O. Livorno; U.O. Ematologia Clinica</name>
      <address>
        <city>Livorno</city>
        <state>Toscana</state>
        <zip>57124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National Uni Hospital; Dept. of Internal Medicine/Hematology/Oncology</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Centre; Division of Hematology/Oncology</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RECUH, Oncology Centre of Latvia; Clinic of Chemotherapy and Heamatology</name>
      <address>
        <city>Riga</city>
        <zip>1079</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health. Sciences Kaunas Clinics</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santariskiu Clinic, Hematology, Oncology and Tranfusion Medicine Center</name>
      <address>
        <city>Vilnius</city>
        <zip>08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General De Culiacan; Servicio De Hematologia</name>
      <address>
        <city>Culiacan</city>
        <zip>80230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de México; Haematology</name>
      <address>
        <city>Mexico City</city>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Nacional Sxxi - Imss; Haematology</name>
      <address>
        <city>Mexico City</city>
        <zip>11270</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Jose E. Gonzalez; Haematology</name>
      <address>
        <city>Monterrey</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios Clinicos de Queretaro (CECLIQ)</name>
      <address>
        <city>Queretaro</city>
        <zip>76000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic of Hematology Skopje, Hospital Care Department</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>North Macedonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Hematoonkologii i Transplantacji Szpiku; Uniwersytetu Medycznego w Lublinie</name>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddzial Kliniczny Hematologii SPZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-228</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewodzki w Opolu, Oddzial Hematologii i Onkologii Hematologicznej</name>
      <address>
        <city>Opole</city>
        <zip>45-061</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im. J. Korczaka; Oddział Chorób Wewnetrznych/Hematologiczny</name>
      <address>
        <city>Slupsk</city>
        <zip>76-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Maria; Servico de Hematologia e Transplantacao de Medula</name>
      <address>
        <city>Lisboa</city>
        <zip>1600</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPO do Porto; Servico de Onco-Hematologia</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinica de Diagnostic Rapid</name>
      <address>
        <city>Brasov</city>
        <zip>500152</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Brasov; Clinica de Hematologie</name>
      <address>
        <city>Brasov</city>
        <zip>500326</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Coltea; Clinica de Hematologie</name>
      <address>
        <city>Bucuresti</city>
        <zip>030171</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic municipal de Urgenta Timisoara; Clinica de Hematologie</name>
      <address>
        <city>Timisoara</city>
        <zip>300079</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI Russian Oncology Research Center n.a. Blokhin of MOH RF</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vladimirskiy Regional Scientific Research Inst. ; Hematology</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almazov Federal Heart, Blood and Endocrinilogy Centre; Hematology department</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Oncology Center</name>
      <address>
        <city>Volgograd</city>
        <zip>400138</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultna Nemocnica Roosevelta; Dept. of Haematology</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>975 17</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Oncology Inst. ; Dept. of Haematology</name>
      <address>
        <city>Bratislava</city>
        <zip>833 10</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Celje; Haematology Dept</name>
      <address>
        <city>Celje</city>
        <zip>3000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Ljubljana; Haematology Dept</name>
      <address>
        <city>Ljubljana</city>
        <zip>1525</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Maribor; Haematology Dept</name>
      <address>
        <city>Maribor</city>
        <zip>2000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital De Txagorritxu; Servicio de Hematologia</name>
      <address>
        <city>Vitoria</city>
        <state>Alava</state>
        <zip>01009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08915</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario San Millan - San Pedro; Servicio Hematologia</name>
      <address>
        <city>Logroño</city>
        <state>LA Rioja</state>
        <zip>26006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Quiron de Madrid; Servicio de Hematologia</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro De Alcantara; Servicio de Hematologia</name>
      <address>
        <city>Caceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia; Servicio de Hematologia</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Leonor; Servicio de Hematologia</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clínico San Carlos; Servicio de Hematología</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Ourense, Servicio de Hematologia</name>
      <address>
        <city>Orense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio; Servicio de Hematologia</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Fe; Servicio de Hematologia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset i Linköping, Hematologkliniken</name>
      <address>
        <city>Linkoeping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital Malmo/Lund, Dept.of Hematology and Coagulation Disorders</name>
      <address>
        <city>Malmö</city>
        <zip>212 24</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uddevalla Sjukhus; Medicinkliniken</name>
      <address>
        <city>Uddevalla</city>
        <zip>45180</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau; Zentrum Für Onkologie, Hämatologie &amp; Transfusionsmedizin</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel; Hämatologie</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana (IOSI)</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden;Onkologie und Hämatologie</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUG; Hématologie</name>
      <address>
        <city>Geneve</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital, Hämatologie</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OnkoZentrum Zuerich</name>
      <address>
        <city>Zürich</city>
        <zip>8038</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital; Division of Hematology, Department of Medicine</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital; Division of Hematology, Department of Medicine</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital; Division of Hematology, Department of Medicine</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Mai Uni Hospital; Division of Hematology,Dept of Medicine,Faculty of Medicine</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital, Khon Kaen Uni ; Dept of Medicine</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cukurova Uni ; Hematology</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara Numune Egitim Ve Arastirma Hastanesi; Hematoloji Klinigi</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara University; Hematology</name>
      <address>
        <city>Ankara</city>
        <zip>06620</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pamukkale Uni. Med. Fac.</name>
      <address>
        <city>Denizli</city>
        <zip>20070</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gaziantep University Medical School; Hematology</name>
      <address>
        <city>Gaziantep</city>
        <zip>27310</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Uni Capa Hospital; Hematology</name>
      <address>
        <city>Istanbul</city>
        <zip>34390</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul Uni ; Hematology</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erciyes Uni ; Hematology</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ondokuzmayis University Medical Faculty Heamatology Department</name>
      <address>
        <city>Samsun</city>
        <zip>55139</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karadeniz Technical Uni School of Medicine; Hematology</name>
      <address>
        <city>Trabzon</city>
        <zip>61800</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Bosnia and Herzegovina</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Egypt</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>North Macedonia</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Thailand</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Albania</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Uruguay</country>
  </removed_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 19, 2013</study_first_submitted>
  <study_first_submitted_qc>July 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2013</study_first_posted>
  <results_first_submitted>December 21, 2017</results_first_submitted>
  <results_first_submitted_qc>October 26, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 29, 2018</results_first_posted>
  <last_update_submitted>October 24, 2019</last_update_submitted>
  <last_update_submitted_qc>October 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Chlorambucil</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 195 centers in 31 countries</recruitment_details>
      <pre_assignment_details>A total of 1131 subjects were screened and 979 subjects were enrolled. Due to compliance issues a site in Romania was closed. Seven subjects were excluded from the analysis, because data integrity was impacted by the site’s non-compliance. Hence, data analysis is reported for 972 enrolled subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Obinutuzumab</title>
          <description>Participants received obinutuzumab either alone as single agent, or in combination with chemotherapy (Fludarabine/Cyclophosphamide [FC], Bendamustine or Chlorambucil).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="972"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="658">All patients provide reason at final analysis</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="314"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal of consent</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator discretion</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="186"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The intent-to-treat (ITT) population was defined as all participants enrolled in the study regardless of whether or not they received any study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Obinutuzumab</title>
          <description>Participants received obinutuzumab either alone as single agent, or in combination with chemotherapy (Fludarabine/Cyclophosphamide [FC], Bendamustine or Chlorambucil).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="972"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.4" spread="10.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="355"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs)</title>
        <description>An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs, including AEs of Special Interest and AEs of Particular Interest, were reported based on the national cancer institute common terminology criteria for AEs, Version 4.0 (NCI-CTCAE, v4.0). Reported are the number of subjects with AEs, Grade 3-5 AEs, and Serious Adverse Events (SAEs).</description>
        <time_frame>Baseline up to time of primary completion (3 years)</time_frame>
        <population>The safety population was defined as all participants who have received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Obinutuzumab</title>
            <description>Participants received obinutuzumab either alone as single agent, or in combination with chemotherapy (Fludarabine/Cyclophosphamide [FC], Bendamustine or Chlorambucil).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs)</title>
          <description>An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs, including AEs of Special Interest and AEs of Particular Interest, were reported based on the national cancer institute common terminology criteria for AEs, Version 4.0 (NCI-CTCAE, v4.0). Reported are the number of subjects with AEs, Grade 3-5 AEs, and Serious Adverse Events (SAEs).</description>
          <population>The safety population was defined as all participants who have received at least one dose of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="971"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-5 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events of Special Interest (AESIs)</title>
        <description>The following AEs were defined as AESIs: AEs with the preferred term Tumour Lysis Syndrome (TLS), Infusion-Related Reactions (IRRs) defined as AEs that occurred during or within 24 hours of the completion of obinutuzumab infusion and were assessed as related to obinutuzumab by the Investigator, Infections defined as AEs from System Organ Class (SOC) &quot;Infections and infestations&quot; and AEs with the preferred term Neutropenia. Reported are number of participants with total AESIs, IRRs, Infections, Neutropenia and TLS.</description>
        <time_frame>Baseline up to time of primary completion (3 years)</time_frame>
        <population>The safety population was defined as all participants who have received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Obinutuzumab</title>
            <description>Participants received obinutuzumab either alone as single agent, or in combination with chemotherapy (Fludarabine/Cyclophosphamide [FC], Bendamustine or Chlorambucil).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events of Special Interest (AESIs)</title>
          <description>The following AEs were defined as AESIs: AEs with the preferred term Tumour Lysis Syndrome (TLS), Infusion-Related Reactions (IRRs) defined as AEs that occurred during or within 24 hours of the completion of obinutuzumab infusion and were assessed as related to obinutuzumab by the Investigator, Infections defined as AEs from System Organ Class (SOC) &quot;Infections and infestations&quot; and AEs with the preferred term Neutropenia. Reported are number of participants with total AESIs, IRRs, Infections, Neutropenia and TLS.</description>
          <population>The safety population was defined as all participants who have received at least one dose of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="971"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total AESIs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="905"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IRRs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events of Particular Interest (AEPIs)</title>
        <description>The following AEs were defined as AEPIs: AEs with the preferred term Progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation defined as AEs with preferred term containing &quot;Hepatitis B&quot; or &quot;hepatitis acute&quot;, thrombocytopenia defined via Roche MedDRA basket subgroup &quot;haematopoietic thrombocytopenia&quot;, second malignancies defined as AEs from the SOC &quot;Neoplasms benign, malignant and unspecified&quot; starting 6 months after the first study drug intake, second malignancies based on standardised MedDRA queries (SMQ) starting 6 months after the first study drug intake based on the MedDRA SMQ &quot;Malignant or unspecified tumours&quot;, in which benign neoplasms are not included, Cardiac events including AEs from the SOC &quot;Cardiac disorders&quot;, and hemorrhagic events defined via Roche MedDRA basket subgroup &quot;Haemorrhagic events&quot;. Reported are number of participants with total AEPIs and each of the AEPI categories.</description>
        <time_frame>Baseline up to time of primary completion (3 years)</time_frame>
        <population>The safety population was defined as all participants who have received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Obinutuzumab</title>
            <description>Participants received obinutuzumab either alone as single agent, or in combination with chemotherapy (Fludarabine/Cyclophosphamide [FC], Bendamustine or Chlorambucil).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events of Particular Interest (AEPIs)</title>
          <description>The following AEs were defined as AEPIs: AEs with the preferred term Progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation defined as AEs with preferred term containing &quot;Hepatitis B&quot; or &quot;hepatitis acute&quot;, thrombocytopenia defined via Roche MedDRA basket subgroup &quot;haematopoietic thrombocytopenia&quot;, second malignancies defined as AEs from the SOC &quot;Neoplasms benign, malignant and unspecified&quot; starting 6 months after the first study drug intake, second malignancies based on standardised MedDRA queries (SMQ) starting 6 months after the first study drug intake based on the MedDRA SMQ &quot;Malignant or unspecified tumours&quot;, in which benign neoplasms are not included, Cardiac events including AEs from the SOC &quot;Cardiac disorders&quot;, and hemorrhagic events defined via Roche MedDRA basket subgroup &quot;Haemorrhagic events&quot;. Reported are number of participants with total AEPIs and each of the AEPI categories.</description>
          <population>The safety population was defined as all participants who have received at least one dose of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="971"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total AEPIs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second malignancies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second malignancies (SMQ)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemorrhagic events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis B reactivation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PML</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Overall Response (OR) at Final Response Assessment (FRA)</title>
        <description>OR: percentage of participants with complete response (CR) or CR with incomplete marrow recovery (CRi), or partial response (PR), as determined by the investigator based on International Workshop on Chronic Lymphocytic Leukemia (IWCLL) tumor response criteria. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils &gt;1,500/mcL, platelets &gt; 100,000/mcL, hemoglobin &gt; 110 g/L and bone marrow normocellular for age. Cri: CR with persistent cytopenia. PR: &gt;/= 50% decrease in peripheral blood lymphocyte count AND &gt;/= 50% reduction in lymphadenopathy OR &gt;/= 50% reduction of liver enlargement OR &gt;/= 50% reduction of spleen PLUS one of the following: neutrophils &gt;1,500/mcL, platelets &gt; 100,000/mcL, hemoglobin &gt; 110 g/L OR &gt;/= 50% increase in neutrophils, platelets or hemoglobin.</description>
        <time_frame>3 months after the last dose of study treatment (up to approximately 5 years)</time_frame>
        <population>The ITT population was defined as all participants enrolled in the study regardless of whether or not they received any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>G Mono: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab monotherapy who were previously untreated fit. Fit participants were defined as having a total Cumulative Illness Rating Scale (CIRS) score ≤6 and creatinine clearance (CrCl) ≥70 mL/min.</description>
          </group>
          <group group_id="O2">
            <title>G Mono: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab monotherapy who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O3">
            <title>G Mono: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab monotherapy who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
          <group group_id="O4">
            <title>G-Benda: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with bendamustine who were previously untreated fit. Fit participants were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O5">
            <title>G-Benda: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with bendamustine who were previously untreated unfit. Non fit Participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O6">
            <title>G-Benda: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with bendamustine who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
          <group group_id="O7">
            <title>G-FC: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who were previously untreated fit. Fit subjects were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O8">
            <title>G-FC: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min. This is a Protocol deviation: unfit subjects were incorrectly assigned to the G-FC treatment regimen.</description>
          </group>
          <group group_id="O9">
            <title>G-FC: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who had documented relapsed/refractory chronic lymphocytic leukemia (CLL). This is a Protocol deviation: 5 unfit subjects were incorrectly assigned to this relapsed/refractory G-FC treatment regimen.</description>
          </group>
          <group group_id="O10">
            <title>G-Clb: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who were previously untreated fit. Fit participants were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O11">
            <title>G-Clb: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O12">
            <title>G-Clb: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Overall Response (OR) at Final Response Assessment (FRA)</title>
          <description>OR: percentage of participants with complete response (CR) or CR with incomplete marrow recovery (CRi), or partial response (PR), as determined by the investigator based on International Workshop on Chronic Lymphocytic Leukemia (IWCLL) tumor response criteria. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils &gt;1,500/mcL, platelets &gt; 100,000/mcL, hemoglobin &gt; 110 g/L and bone marrow normocellular for age. Cri: CR with persistent cytopenia. PR: &gt;/= 50% decrease in peripheral blood lymphocyte count AND &gt;/= 50% reduction in lymphadenopathy OR &gt;/= 50% reduction of liver enlargement OR &gt;/= 50% reduction of spleen PLUS one of the following: neutrophils &gt;1,500/mcL, platelets &gt; 100,000/mcL, hemoglobin &gt; 110 g/L OR &gt;/= 50% increase in neutrophils, platelets or hemoglobin.</description>
          <population>The ITT population was defined as all participants enrolled in the study regardless of whether or not they received any study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="168"/>
                <count group_id="O5" value="179"/>
                <count group_id="O6" value="190"/>
                <count group_id="O7" value="140"/>
                <count group_id="O8" value="13"/>
                <count group_id="O9" value="40"/>
                <count group_id="O10" value="1"/>
                <count group_id="O11" value="67"/>
                <count group_id="O12" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0" lower_limit="52.0" upper_limit="85.8"/>
                    <measurement group_id="O2" value="59.4" lower_limit="40.6" upper_limit="76.3"/>
                    <measurement group_id="O3" value="41.5" lower_limit="29.4" upper_limit="54.4"/>
                    <measurement group_id="O4" value="83.9" lower_limit="77.5" upper_limit="89.1"/>
                    <measurement group_id="O5" value="81.6" lower_limit="75.1" upper_limit="87.0"/>
                    <measurement group_id="O6" value="73.2" lower_limit="66.3" upper_limit="79.3"/>
                    <measurement group_id="O7" value="90.0" lower_limit="83.8" upper_limit="94.4"/>
                    <measurement group_id="O8" value="84.6" lower_limit="54.6" upper_limit="98.1"/>
                    <measurement group_id="O9" value="85.0" lower_limit="70.2" upper_limit="94.3"/>
                    <measurement group_id="O10" value="100" lower_limit="2.5" upper_limit="100.0"/>
                    <measurement group_id="O11" value="82.1" lower_limit="70.8" upper_limit="90.4"/>
                    <measurement group_id="O12" value="56.5" lower_limit="41.1" upper_limit="71.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Minimal Residual Disease (MRD)-Negativity as Assessed by Flow Cytometry</title>
        <description>MRD-negativity was defined as the presence of less than 1 chronic lymphocytic leukemia (CLL) cell per 10,000 leukocytes in blood and bone marrow as assessed by flow cytometry 3 months after last dose of study treatment (i.e. at final response assessment [FRA] visit).</description>
        <time_frame>3 months after the last dose of study treatment (up to approximately 5 years)</time_frame>
        <population>The intent-to-ship (ITS) population included all participants from the ITT population whose MRD samples at the FRA could be shipped to the central laboratory within 48 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>G Mono: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab monotherapy who were previously untreated fit. Fit participants were defined as having a total Cumulative Illness Rating Scale (CIRS) score ≤6 and creatinine clearance (CrCl) ≥70 mL/min.</description>
          </group>
          <group group_id="O2">
            <title>G Mono: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab monotherapy who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O3">
            <title>G Mono: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab monotherapy who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
          <group group_id="O4">
            <title>G-Benda: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with bendamustine who were previously untreated fit. Fit participants were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O5">
            <title>G-Benda: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with bendamustine who were previously untreated unfit. Non fit Participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O6">
            <title>G-Benda: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with bendamustine who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
          <group group_id="O7">
            <title>G-FC: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who were previously untreated fit. Fit subjects were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O8">
            <title>G-FC: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min. This is a Protocol deviation: unfit subjects were incorrectly assigned to the G-FC treatment regimen.</description>
          </group>
          <group group_id="O9">
            <title>G-FC: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who had documented relapsed/refractory chronic lymphocytic leukemia (CLL). This is a Protocol deviation: 5 unfit subjects were incorrectly assigned to this relapsed/refractory G-FC treatment regimen.</description>
          </group>
          <group group_id="O10">
            <title>G-Clb: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who were previously untreated fit. Fit participants were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O11">
            <title>G-Clb: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O12">
            <title>G-Clb: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Minimal Residual Disease (MRD)-Negativity as Assessed by Flow Cytometry</title>
          <description>MRD-negativity was defined as the presence of less than 1 chronic lymphocytic leukemia (CLL) cell per 10,000 leukocytes in blood and bone marrow as assessed by flow cytometry 3 months after last dose of study treatment (i.e. at final response assessment [FRA] visit).</description>
          <population>The intent-to-ship (ITS) population included all participants from the ITT population whose MRD samples at the FRA could be shipped to the central laboratory within 48 hours.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="168"/>
                <count group_id="O5" value="179"/>
                <count group_id="O6" value="190"/>
                <count group_id="O7" value="140"/>
                <count group_id="O8" value="13"/>
                <count group_id="O9" value="40"/>
                <count group_id="O10" value="1"/>
                <count group_id="O11" value="67"/>
                <count group_id="O12" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="149"/>
                    <count group_id="O5" value="147"/>
                    <count group_id="O6" value="161"/>
                    <count group_id="O7" value="125"/>
                    <count group_id="O8" value="12"/>
                    <count group_id="O9" value="33"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="53"/>
                    <count group_id="O12" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="23.1"/>
                    <measurement group_id="O3" value="4.1"/>
                    <measurement group_id="O4" value="63.1"/>
                    <measurement group_id="O5" value="65.3"/>
                    <measurement group_id="O6" value="39.8"/>
                    <measurement group_id="O7" value="72.0"/>
                    <measurement group_id="O8" value="58.3"/>
                    <measurement group_id="O9" value="51.5"/>
                    <measurement group_id="O11" value="9.4"/>
                    <measurement group_id="O12" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Marrow</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="149"/>
                    <count group_id="O5" value="147"/>
                    <count group_id="O6" value="161"/>
                    <count group_id="O7" value="125"/>
                    <count group_id="O8" value="12"/>
                    <count group_id="O9" value="33"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="53"/>
                    <count group_id="O12" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="3.8"/>
                    <measurement group_id="O3" value="2.0"/>
                    <measurement group_id="O4" value="31.5"/>
                    <measurement group_id="O5" value="27.2"/>
                    <measurement group_id="O6" value="14.9"/>
                    <measurement group_id="O7" value="40.0"/>
                    <measurement group_id="O8" value="41.7"/>
                    <measurement group_id="O9" value="24.2"/>
                    <measurement group_id="O11" value="5.7"/>
                    <measurement group_id="O12" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Best Overall Response (BOR)</title>
        <description>BOR was defined as the percentage of participants with the best response obtained throughout the trial with CR, CRi, or PR, as determined by the investigator based on IWCLL tumor response criteria. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils &gt;1,500/mcL, platelets &gt; 100,000/mcL, hemoglobin &gt; 110 g/L and bone marrow normocellular for age. Cri: CR with persistent cytopenia. PR: &gt;/= 50% decrease in peripheral blood lymphocyte count AND &gt;/= 50% reduction in lymphadenopathy OR &gt;/= 50% reduction of liver enlargement OR &gt;/= 50% reduction of spleen PLUS one of the following: neutrophils &gt;1,500/mcL, platelets &gt; 100,000/mcL, hemoglobin &gt; 110 g/L OR &gt;/= 50% increase in neutrophils, platelets or hemoglobin.</description>
        <time_frame>Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)</time_frame>
        <population>The ITT population was defined as all participants enrolled in the study regardless of whether or not they received any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>G Mono: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab monotherapy who were previously untreated fit. Fit participants were defined as having a total Cumulative Illness Rating Scale (CIRS) score ≤6 and creatinine clearance (CrCl) ≥70 mL/min.</description>
          </group>
          <group group_id="O2">
            <title>G Mono: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab monotherapy who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O3">
            <title>G Mono: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab monotherapy who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
          <group group_id="O4">
            <title>G-Benda: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with bendamustine who were previously untreated fit. Fit participants were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O5">
            <title>G-Benda: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with bendamustine who were previously untreated unfit. Non fit Participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O6">
            <title>G-Benda: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with bendamustine who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
          <group group_id="O7">
            <title>G-FC: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who were previously untreated fit. Fit subjects were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O8">
            <title>G-FC: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min. This is a Protocol deviation: unfit subjects were incorrectly assigned to the G-FC treatment regimen.</description>
          </group>
          <group group_id="O9">
            <title>G-FC: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who had documented relapsed/refractory chronic lymphocytic leukemia (CLL). This is a Protocol deviation: 5 unfit subjects were incorrectly assigned to this relapsed/refractory G-FC treatment regimen.</description>
          </group>
          <group group_id="O10">
            <title>G-Clb: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who were previously untreated fit. Fit participants were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O11">
            <title>G-Clb: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O12">
            <title>G-Clb: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Best Overall Response (BOR)</title>
          <description>BOR was defined as the percentage of participants with the best response obtained throughout the trial with CR, CRi, or PR, as determined by the investigator based on IWCLL tumor response criteria. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils &gt;1,500/mcL, platelets &gt; 100,000/mcL, hemoglobin &gt; 110 g/L and bone marrow normocellular for age. Cri: CR with persistent cytopenia. PR: &gt;/= 50% decrease in peripheral blood lymphocyte count AND &gt;/= 50% reduction in lymphadenopathy OR &gt;/= 50% reduction of liver enlargement OR &gt;/= 50% reduction of spleen PLUS one of the following: neutrophils &gt;1,500/mcL, platelets &gt; 100,000/mcL, hemoglobin &gt; 110 g/L OR &gt;/= 50% increase in neutrophils, platelets or hemoglobin.</description>
          <population>The ITT population was defined as all participants enrolled in the study regardless of whether or not they received any study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="168"/>
                <count group_id="O5" value="179"/>
                <count group_id="O6" value="190"/>
                <count group_id="O7" value="140"/>
                <count group_id="O8" value="13"/>
                <count group_id="O9" value="40"/>
                <count group_id="O10" value="1"/>
                <count group_id="O11" value="67"/>
                <count group_id="O12" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.9" lower_limit="66.3" upper_limit="94.5"/>
                    <measurement group_id="O2" value="71.9" lower_limit="53.3" upper_limit="86.3"/>
                    <measurement group_id="O3" value="60.0" lower_limit="47.1" upper_limit="72.0"/>
                    <measurement group_id="O4" value="91.7" lower_limit="86.4" upper_limit="95.4"/>
                    <measurement group_id="O5" value="93.9" lower_limit="89.3" upper_limit="96.9"/>
                    <measurement group_id="O6" value="86.8" lower_limit="81.2" upper_limit="91.3"/>
                    <measurement group_id="O7" value="97.1" lower_limit="92.8" upper_limit="99.2"/>
                    <measurement group_id="O8" value="84.6" lower_limit="54.6" upper_limit="98.1"/>
                    <measurement group_id="O9" value="97.5" lower_limit="86.8" upper_limit="99.9"/>
                    <measurement group_id="O10" value="100" lower_limit="2.5" upper_limit="100.0"/>
                    <measurement group_id="O11" value="94.0" lower_limit="85.4" upper_limit="98.3"/>
                    <measurement group_id="O12" value="84.8" lower_limit="71.1" upper_limit="93.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Progression-Free Survival (PFS)</title>
        <description>Kaplan Meier estimate of the median PFS was defined as the time at which half of the participants have progressed (progressive disease [PD]) based on IWCLL tumor response criteria or died from any cause, whichever occurred first. PD: at least one of the following: &gt;/= 50% increase in the absolute number of circulating lymphocytes to at least 5,000/mcL, appearance of new palpable lymph nodes, &gt;/= 50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, &gt;/= 50% increase in the enlargement of the liver and/or spleen, transformation to more aggressive histology, progression of any cytopenia, decrease of hemoglobin levels by more than 20 g/L or to less than 100 g/L, decrease of platelet counts by more than 50% or to less than 100,000 /mcL, decrease of neutrophil counts by more than 50% or to less than 1,000/mcL.</description>
        <time_frame>Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)</time_frame>
        <population>The ITT population was defined as all participants enrolled in the study regardless of whether or not they received any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>G Mono: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab monotherapy who were previously untreated fit. Fit participants were defined as having a total Cumulative Illness Rating Scale (CIRS) score ≤6 and creatinine clearance (CrCl) ≥70 mL/min.</description>
          </group>
          <group group_id="O2">
            <title>G Mono: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab monotherapy who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O3">
            <title>G Mono: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab monotherapy who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
          <group group_id="O4">
            <title>G-Benda: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with bendamustine who were previously untreated fit. Fit participants were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O5">
            <title>G-Benda: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with bendamustine who were previously untreated unfit. Non fit Participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O6">
            <title>G-Benda: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with bendamustine who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
          <group group_id="O7">
            <title>G-FC: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who were previously untreated fit. Fit subjects were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O8">
            <title>G-FC: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min. This is a Protocol deviation: unfit subjects were incorrectly assigned to the G-FC treatment regimen.</description>
          </group>
          <group group_id="O9">
            <title>G-FC: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who had documented relapsed/refractory chronic lymphocytic leukemia (CLL). This is a Protocol deviation: 5 unfit subjects were incorrectly assigned to this relapsed/refractory G-FC treatment regimen.</description>
          </group>
          <group group_id="O10">
            <title>G-Clb: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who were previously untreated fit. Fit participants were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O11">
            <title>G-Clb: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O12">
            <title>G-Clb: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Progression-Free Survival (PFS)</title>
          <description>Kaplan Meier estimate of the median PFS was defined as the time at which half of the participants have progressed (progressive disease [PD]) based on IWCLL tumor response criteria or died from any cause, whichever occurred first. PD: at least one of the following: &gt;/= 50% increase in the absolute number of circulating lymphocytes to at least 5,000/mcL, appearance of new palpable lymph nodes, &gt;/= 50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, &gt;/= 50% increase in the enlargement of the liver and/or spleen, transformation to more aggressive histology, progression of any cytopenia, decrease of hemoglobin levels by more than 20 g/L or to less than 100 g/L, decrease of platelet counts by more than 50% or to less than 100,000 /mcL, decrease of neutrophil counts by more than 50% or to less than 1,000/mcL.</description>
          <population>The ITT population was defined as all participants enrolled in the study regardless of whether or not they received any study drug.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="168"/>
                <count group_id="O5" value="179"/>
                <count group_id="O6" value="190"/>
                <count group_id="O7" value="140"/>
                <count group_id="O8" value="13"/>
                <count group_id="O9" value="40"/>
                <count group_id="O10" value="1"/>
                <count group_id="O11" value="67"/>
                <count group_id="O12" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.0" lower_limit="17.0" upper_limit="NA">Upper limit of 95% CI could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O2" value="21.2" lower_limit="14.9" upper_limit="NA">Upper limit of 95% CI could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O3" value="17.6" lower_limit="12.5" upper_limit="20.0"/>
                    <measurement group_id="O4" value="58.0" lower_limit="44.5" upper_limit="58.0"/>
                    <measurement group_id="O5" value="NA" lower_limit="45.4" upper_limit="NA">Median and Upper Limit 95% CI could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O6" value="28.6" lower_limit="24.2" upper_limit="31.1"/>
                    <measurement group_id="O7" value="NA" lower_limit="53.7" upper_limit="NA">Median and Upper Limit 95% CI could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="19.0" upper_limit="NA">Median and Upper Limit 95% CI could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O9" value="24.8" lower_limit="19.3" upper_limit="35.0"/>
                    <measurement group_id="O10" value="31.3" lower_limit="NA" upper_limit="NA">95% CI could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O11" value="31.8" lower_limit="27.7" upper_limit="36.4"/>
                    <measurement group_id="O12" value="14.1" lower_limit="10.8" upper_limit="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Response (TTR)</title>
        <description>Kaplan Meier estimate of median TTR was defined as the time at which half of the participants reached CR or PR based on IWCLL tumor response criteria. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils &gt;1,500/mcL, platelets &gt; 100,000/mcL, hemoglobin &gt; 110 g/L and bone marrow normocellular for age. PR: &gt;/= 50% decrease in peripheral blood lymphocyte count AND &gt;/= 50% reduction in lymphadenopathy OR &gt;/= 50% reduction of liver enlargement OR &gt;/= 50% reduction of spleen PLUS one of the following: neutrophils &gt;1,500/mcL, platelets &gt; 100,000/mcL, hemoglobin &gt; 110 g/L OR &gt;/= 50% increase in neutrophils, platelets or hemoglobin.</description>
        <time_frame>Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)</time_frame>
        <population>The ITT population was defined as all participants enrolled in the study regardless of whether or not they received any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>G Mono: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab monotherapy who were previously untreated fit. Fit participants were defined as having a total Cumulative Illness Rating Scale (CIRS) score ≤6 and creatinine clearance (CrCl) ≥70 mL/min.</description>
          </group>
          <group group_id="O2">
            <title>G Mono: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab monotherapy who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O3">
            <title>G Mono: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab monotherapy who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
          <group group_id="O4">
            <title>G-Benda: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with bendamustine who were previously untreated fit. Fit participants were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O5">
            <title>G-Benda: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with bendamustine who were previously untreated unfit. Non fit Participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O6">
            <title>G-Benda: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with bendamustine who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
          <group group_id="O7">
            <title>G-FC: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who were previously untreated fit. Fit subjects were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O8">
            <title>G-FC: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min. This is a Protocol deviation: unfit subjects were incorrectly assigned to the G-FC treatment regimen.</description>
          </group>
          <group group_id="O9">
            <title>G-FC: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who had documented relapsed/refractory chronic lymphocytic leukemia (CLL). This is a Protocol deviation: 5 unfit subjects were incorrectly assigned to this relapsed/refractory G-FC treatment regimen.</description>
          </group>
          <group group_id="O10">
            <title>G-Clb: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who were previously untreated fit. Fit participants were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O11">
            <title>G-Clb: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O12">
            <title>G-Clb: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Response (TTR)</title>
          <description>Kaplan Meier estimate of median TTR was defined as the time at which half of the participants reached CR or PR based on IWCLL tumor response criteria. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils &gt;1,500/mcL, platelets &gt; 100,000/mcL, hemoglobin &gt; 110 g/L and bone marrow normocellular for age. PR: &gt;/= 50% decrease in peripheral blood lymphocyte count AND &gt;/= 50% reduction in lymphadenopathy OR &gt;/= 50% reduction of liver enlargement OR &gt;/= 50% reduction of spleen PLUS one of the following: neutrophils &gt;1,500/mcL, platelets &gt; 100,000/mcL, hemoglobin &gt; 110 g/L OR &gt;/= 50% increase in neutrophils, platelets or hemoglobin.</description>
          <population>The ITT population was defined as all participants enrolled in the study regardless of whether or not they received any study drug.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="168"/>
                <count group_id="O5" value="179"/>
                <count group_id="O6" value="190"/>
                <count group_id="O7" value="140"/>
                <count group_id="O8" value="13"/>
                <count group_id="O9" value="40"/>
                <count group_id="O10" value="1"/>
                <count group_id="O11" value="67"/>
                <count group_id="O12" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="3.2" upper_limit="3.8"/>
                    <measurement group_id="O2" value="3.6" lower_limit="3.3" upper_limit="3.9"/>
                    <measurement group_id="O3" value="3.9" lower_limit="3.7" upper_limit="4.4"/>
                    <measurement group_id="O4" value="3.5" lower_limit="3.4" upper_limit="3.6"/>
                    <measurement group_id="O5" value="3.5" lower_limit="3.5" upper_limit="3.7"/>
                    <measurement group_id="O6" value="3.7" lower_limit="3.5" upper_limit="3.7"/>
                    <measurement group_id="O7" value="3.6" lower_limit="3.5" upper_limit="3.7"/>
                    <measurement group_id="O8" value="4.1" lower_limit="3.3" upper_limit="7.9"/>
                    <measurement group_id="O9" value="3.6" lower_limit="3.4" upper_limit="3.7"/>
                    <measurement group_id="O10" value="3.3" lower_limit="NA" upper_limit="NA">Lower Limit and Upper limit of 95% CI could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O11" value="3.6" lower_limit="3.4" upper_limit="3.7"/>
                    <measurement group_id="O12" value="3.7" lower_limit="3.5" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Event-Free Survival (EFS)</title>
        <description>Kaplan Meier estimate of median EFS is the time at which half of the participants have progressed as assessed by investigator based on IWCLL tumor response criteria, or have initiated a non-protocol-specified anti-leukemia therapy or died, whichever occurs first. PD: at least 1 of the following: &gt;/= 50% increase in absolute number of circulating lymphocytes to at least 5,000/mcL, appearance of new palpable lymph nodes, &gt;/= 50% increase in longest diameter of any previous site of clinically significant lymphadenopathy, &gt;/= 50% increase in enlargement of liver and/or spleen, transformation to more aggressive histology, progression of any cytopenia, decrease of hemoglobin levels by more than 20 g/L or to less than 100 g/L, decrease of platelet counts by more than 50% or to less than 100,000 /mcL, decrease of neutrophil counts by more than 50% or to less than 1,000/mcL.</description>
        <time_frame>Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)</time_frame>
        <population>The ITT population was defined as all participants enrolled in the study regardless of whether or not they received any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>G Mono: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab monotherapy who were previously untreated fit. Fit participants were defined as having a total Cumulative Illness Rating Scale (CIRS) score ≤6 and creatinine clearance (CrCl) ≥70 mL/min.</description>
          </group>
          <group group_id="O2">
            <title>G Mono: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab monotherapy who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O3">
            <title>G Mono: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab monotherapy who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
          <group group_id="O4">
            <title>G-Benda: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with bendamustine who were previously untreated fit. Fit participants were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O5">
            <title>G-Benda: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with bendamustine who were previously untreated unfit. Non fit Participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O6">
            <title>G-Benda: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with bendamustine who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
          <group group_id="O7">
            <title>G-FC: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who were previously untreated fit. Fit subjects were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O8">
            <title>G-FC: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min. This is a Protocol deviation: unfit subjects were incorrectly assigned to the G-FC treatment regimen.</description>
          </group>
          <group group_id="O9">
            <title>G-FC: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who had documented relapsed/refractory chronic lymphocytic leukemia (CLL). This is a Protocol deviation: 5 unfit subjects were incorrectly assigned to this relapsed/refractory G-FC treatment regimen.</description>
          </group>
          <group group_id="O10">
            <title>G-Clb: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who were previously untreated fit. Fit participants were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O11">
            <title>G-Clb: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O12">
            <title>G-Clb: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Event-Free Survival (EFS)</title>
          <description>Kaplan Meier estimate of median EFS is the time at which half of the participants have progressed as assessed by investigator based on IWCLL tumor response criteria, or have initiated a non-protocol-specified anti-leukemia therapy or died, whichever occurs first. PD: at least 1 of the following: &gt;/= 50% increase in absolute number of circulating lymphocytes to at least 5,000/mcL, appearance of new palpable lymph nodes, &gt;/= 50% increase in longest diameter of any previous site of clinically significant lymphadenopathy, &gt;/= 50% increase in enlargement of liver and/or spleen, transformation to more aggressive histology, progression of any cytopenia, decrease of hemoglobin levels by more than 20 g/L or to less than 100 g/L, decrease of platelet counts by more than 50% or to less than 100,000 /mcL, decrease of neutrophil counts by more than 50% or to less than 1,000/mcL.</description>
          <population>The ITT population was defined as all participants enrolled in the study regardless of whether or not they received any study drug.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="168"/>
                <count group_id="O5" value="179"/>
                <count group_id="O6" value="190"/>
                <count group_id="O7" value="140"/>
                <count group_id="O8" value="13"/>
                <count group_id="O9" value="40"/>
                <count group_id="O10" value="1"/>
                <count group_id="O11" value="67"/>
                <count group_id="O12" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2" lower_limit="15.6" upper_limit="NA">Upper limit of 95% CI could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O2" value="17.9" lower_limit="14.5" upper_limit="NA">Upper limit of 95% CI could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O3" value="14.0" lower_limit="9.1" upper_limit="17.9"/>
                    <measurement group_id="O4" value="58.0" lower_limit="44.5" upper_limit="58.0"/>
                    <measurement group_id="O5" value="52.9" lower_limit="44.7" upper_limit="NA">Upper limit of 95% CI could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O6" value="25.1" lower_limit="21.0" upper_limit="30.4"/>
                    <measurement group_id="O7" value="NA" lower_limit="53.7" upper_limit="NA">Median and Upper limit of 95% CI could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="17.8" upper_limit="NA">Median and Upper limit of 95% CI could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O9" value="24.2" lower_limit="18.7" upper_limit="33.8"/>
                    <measurement group_id="O10" value="31.3" lower_limit="NA" upper_limit="NA">Lower limit and Upper limit of 95% CI could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O11" value="31.8" lower_limit="27.7" upper_limit="36.4"/>
                    <measurement group_id="O12" value="13.7" lower_limit="10.5" upper_limit="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Overall Survival (OS)</title>
        <description>Kaplan Meier estimate of median OS was defined as the time at which half of the participants had died, regardless of the cause of death.</description>
        <time_frame>Baseline until death (Approximately up to 5 years)</time_frame>
        <population>The ITT population was defined as all participants enrolled in the study regardless of whether or not they received any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>G Mono: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab monotherapy who were previously untreated fit. Fit participants were defined as having a total Cumulative Illness Rating Scale (CIRS) score ≤6 and creatinine clearance (CrCl) ≥70 mL/min.</description>
          </group>
          <group group_id="O2">
            <title>G Mono: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab monotherapy who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O3">
            <title>G Mono: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab monotherapy who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
          <group group_id="O4">
            <title>G-Benda: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with bendamustine who were previously untreated fit. Fit participants were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O5">
            <title>G-Benda: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with bendamustine who were previously untreated unfit. Non fit Participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O6">
            <title>G-Benda: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with bendamustine who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
          <group group_id="O7">
            <title>G-FC: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who were previously untreated fit. Fit subjects were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O8">
            <title>G-FC: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min. This is a Protocol deviation: unfit subjects were incorrectly assigned to the G-FC treatment regimen.</description>
          </group>
          <group group_id="O9">
            <title>G-FC: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who had documented relapsed/refractory chronic lymphocytic leukemia (CLL). This is a Protocol deviation: 5 unfit subjects were incorrectly assigned to this relapsed/refractory G-FC treatment regimen.</description>
          </group>
          <group group_id="O10">
            <title>G-Clb: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who were previously untreated fit. Fit participants were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O11">
            <title>G-Clb: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O12">
            <title>G-Clb: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Overall Survival (OS)</title>
          <description>Kaplan Meier estimate of median OS was defined as the time at which half of the participants had died, regardless of the cause of death.</description>
          <population>The ITT population was defined as all participants enrolled in the study regardless of whether or not they received any study drug.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="168"/>
                <count group_id="O5" value="179"/>
                <count group_id="O6" value="190"/>
                <count group_id="O7" value="140"/>
                <count group_id="O8" value="13"/>
                <count group_id="O9" value="40"/>
                <count group_id="O10" value="1"/>
                <count group_id="O11" value="67"/>
                <count group_id="O12" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median and corresponding 95% CI could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="40.7" upper_limit="NA">Median and corresponding 95% CI Upper Limit could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="42.1" upper_limit="NA">Median and corresponding 95% CI Upper Limit could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Median and corresponding 95% CI could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Median and corresponding 95% CI could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="55.3" upper_limit="NA">Median and corresponding 95% CI Upper Limit could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Median and corresponding 95% CI could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Median and corresponding 95% CI could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">Median and corresponding 95% CI could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O10" value="NA" lower_limit="NA" upper_limit="NA">Median and corresponding 95% CI could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O11" value="NA" lower_limit="NA" upper_limit="NA">Median and corresponding 95% CI could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O12" value="NA" lower_limit="35.2" upper_limit="NA">Median and corresponding 95% CI Upper Limit could not be estimated as too few patients had an event.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to New Anti-Leukemia Therapy (TTNT)</title>
        <description>Kaplan Meier estimate of median TTNT was defined as the time at which half of the participants have initiated a new anti-leukemic therapy.</description>
        <time_frame>Baseline until end of study (up to approximately 5 years)</time_frame>
        <population>The ITT population was defined as all participants enrolled in the study regardless of whether or not they received any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>G Mono: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab monotherapy who were previously untreated fit. Fit participants were defined as having a total Cumulative Illness Rating Scale (CIRS) score ≤6 and creatinine clearance (CrCl) ≥70 mL/min.</description>
          </group>
          <group group_id="O2">
            <title>G Mono: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab monotherapy who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O3">
            <title>G Mono: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab monotherapy who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
          <group group_id="O4">
            <title>G-Benda: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with bendamustine who were previously untreated fit. Fit participants were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O5">
            <title>G-Benda: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with bendamustine who were previously untreated unfit. Non fit Participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O6">
            <title>G-Benda: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with bendamustine who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
          <group group_id="O7">
            <title>G-FC: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who were previously untreated fit. Fit subjects were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O8">
            <title>G-FC: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min. This is a Protocol deviation: unfit subjects were incorrectly assigned to the G-FC treatment regimen.</description>
          </group>
          <group group_id="O9">
            <title>G-FC: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who had documented relapsed/refractory chronic lymphocytic leukemia (CLL). This is a Protocol deviation: 5 unfit subjects were incorrectly assigned to this relapsed/refractory G-FC treatment regimen.</description>
          </group>
          <group group_id="O10">
            <title>G-Clb: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who were previously untreated fit. Fit participants were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O11">
            <title>G-Clb: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O12">
            <title>G-Clb: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to New Anti-Leukemia Therapy (TTNT)</title>
          <description>Kaplan Meier estimate of median TTNT was defined as the time at which half of the participants have initiated a new anti-leukemic therapy.</description>
          <population>The ITT population was defined as all participants enrolled in the study regardless of whether or not they received any study drug.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="168"/>
                <count group_id="O5" value="179"/>
                <count group_id="O6" value="190"/>
                <count group_id="O7" value="140"/>
                <count group_id="O8" value="13"/>
                <count group_id="O9" value="40"/>
                <count group_id="O10" value="1"/>
                <count group_id="O11" value="67"/>
                <count group_id="O12" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="25.0" upper_limit="NA">Median and corresponding 95% CI Upper Limit could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="27.5" upper_limit="NA">Median and corresponding 95% CI Upper Limit could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O3" value="22.5" lower_limit="14.8" upper_limit="27.0"/>
                    <measurement group_id="O4" value="NA" lower_limit="53.5" upper_limit="NA">Median and corresponding 95% CI Upper Limit could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Median and corresponding 95% CI Lower Limit and Upper Limit could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O6" value="38.3" lower_limit="31.5" upper_limit="42.0"/>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Median and corresponding 95% CI could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="35.0" upper_limit="NA">Median and corresponding 95% CI Upper Limit could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O9" value="32.6" lower_limit="28.2" upper_limit="NA">95% CI Upper Limit could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O10" value="NA" lower_limit="NA" upper_limit="NA">Median and corresponding 95% CI Lower Limit and Upper Limit could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O11" value="53.7" lower_limit="37.1" upper_limit="NA">95% CI Upper Limit could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O12" value="20.4" lower_limit="13.7" upper_limit="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Duration of Response (DoR)</title>
        <description>Kaplan Meier estimate of median DoR was defined as the time at which half of the responding (PR or CR) participants had progressed (PD) or died from any cause, whichever occurred first. PR: &gt;/= 50% decrease in peripheral blood lymphocyte count AND &gt;/= 50% reduction in lymphadenopathy OR &gt;/= 50% reduction of liver enlargement OR &gt;/= 50% reduction of spleen PLUS one of the following: neutrophils &gt;1,500/mcL, platelets &gt; 100,000/mcL, hemoglobin &gt; 110 g/L OR &gt;/= 50% increase in neutrophils, platelets or hemoglobin. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils &gt;1,500/mcL, platelets &gt; 100,000/mcL, hemoglobin &gt; 110 g/L and bone marrow normocellular for age. PD: as defined in the description for Event-Free Survival outcome measure.</description>
        <time_frame>Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)</time_frame>
        <population>The ITT population was defined as all participants enrolled in the study regardless of whether or not they received any study drug. Number of participants analyzed indicates participants who took part in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>G Mono: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab monotherapy who were previously untreated fit. Fit participants were defined as having a total Cumulative Illness Rating Scale (CIRS) score ≤6 and creatinine clearance (CrCl) ≥70 mL/min.</description>
          </group>
          <group group_id="O2">
            <title>G Mono: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab monotherapy who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O3">
            <title>G Mono: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab monotherapy who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
          <group group_id="O4">
            <title>G-Benda: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with bendamustine who were previously untreated fit. Fit participants were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O5">
            <title>G-Benda: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with bendamustine who were previously untreated unfit. Non fit Participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O6">
            <title>G-Benda: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with bendamustine who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
          <group group_id="O7">
            <title>G-FC: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who were previously untreated fit. Fit subjects were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O8">
            <title>G-FC: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min. This is a Protocol deviation: unfit subjects were incorrectly assigned to the G-FC treatment regimen.</description>
          </group>
          <group group_id="O9">
            <title>G-FC: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with fludarabine and cyclophosphamide who had documented relapsed/refractory chronic lymphocytic leukemia (CLL). This is a Protocol deviation: 5 unfit subjects were incorrectly assigned to this relapsed/refractory G-FC treatment regimen.</description>
          </group>
          <group group_id="O10">
            <title>G-Clb: Previously Untreated Fit</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who were previously untreated fit. Fit participants were defined as having a total CIRS score &lt;=6 and CrCl &gt;=70 mL/min.</description>
          </group>
          <group group_id="O11">
            <title>G-Clb: Previously Untreated Unfit</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who were previously untreated unfit. Non fit participants were defined as having a CIRS score &gt;6 and/or CrCl &lt;70 mL/min.</description>
          </group>
          <group group_id="O12">
            <title>G-Clb: Relapsed/Refractory</title>
            <description>Participants with obinutuzumab in combination with chlorambucil who had documented relapsed/refractory chronic lymphocytic leukemia (CLL).</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Duration of Response (DoR)</title>
          <description>Kaplan Meier estimate of median DoR was defined as the time at which half of the responding (PR or CR) participants had progressed (PD) or died from any cause, whichever occurred first. PR: &gt;/= 50% decrease in peripheral blood lymphocyte count AND &gt;/= 50% reduction in lymphadenopathy OR &gt;/= 50% reduction of liver enlargement OR &gt;/= 50% reduction of spleen PLUS one of the following: neutrophils &gt;1,500/mcL, platelets &gt; 100,000/mcL, hemoglobin &gt; 110 g/L OR &gt;/= 50% increase in neutrophils, platelets or hemoglobin. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils &gt;1,500/mcL, platelets &gt; 100,000/mcL, hemoglobin &gt; 110 g/L and bone marrow normocellular for age. PD: as defined in the description for Event-Free Survival outcome measure.</description>
          <population>The ITT population was defined as all participants enrolled in the study regardless of whether or not they received any study drug. Number of participants analyzed indicates participants who took part in the analysis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="168"/>
                <count group_id="O5" value="179"/>
                <count group_id="O6" value="190"/>
                <count group_id="O7" value="140"/>
                <count group_id="O8" value="13"/>
                <count group_id="O9" value="40"/>
                <count group_id="O10" value="1"/>
                <count group_id="O11" value="67"/>
                <count group_id="O12" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.1" lower_limit="26.3" upper_limit="NA">95% CI Upper Limit could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O2" value="20.1" lower_limit="12.1" upper_limit="NA">95% CI Upper Limit could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O3" value="15.0" lower_limit="12.1" upper_limit="19.9"/>
                    <measurement group_id="O4" value="55.0" lower_limit="44.2" upper_limit="55.0"/>
                    <measurement group_id="O5" value="49.3" lower_limit="44.2" upper_limit="NA">95% CI Upper Limit could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O6" value="25.5" lower_limit="21.2" upper_limit="29.7"/>
                    <measurement group_id="O7" value="NA" lower_limit="50.1" upper_limit="NA">Median and corresponding 95% CI Upper Limit could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="48.3" upper_limit="NA">Median and corresponding 95% CI Upper Limit could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O9" value="21.2" lower_limit="15.1" upper_limit="32.1"/>
                    <measurement group_id="O10" value="28.1" lower_limit="NA" upper_limit="NA">95% CI Lower Limit and Upper Limit could not be estimated as too few patients had an event.</measurement>
                    <measurement group_id="O11" value="28.1" lower_limit="24.3" upper_limit="34.8"/>
                    <measurement group_id="O12" value="12.3" lower_limit="7.3" upper_limit="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 5 years</time_frame>
      <desc>The safety population was defined as all participants who received at least one dose of study medication. AEs that were entered into the data base at the time of the data base lock were included in the AE analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>G-Mono</title>
          <description>Participants received obinutuzumab alone as single agent.</description>
        </group>
        <group group_id="E2">
          <title>G-Benda</title>
          <description>Participants received obinutuzumab in combination with bendamustine.</description>
        </group>
        <group group_id="E3">
          <title>G-FC</title>
          <description>Participants received obinutuzumab in combination with fludarabine/cyclophosphamide (FC).</description>
        </group>
        <group group_id="E4">
          <title>G-Clb</title>
          <description>Participants received obinutuzumab in combination with chlorambucil.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="335" subjects_at_risk="537"/>
                <counts group_id="E3" subjects_affected="107" subjects_at_risk="193"/>
                <counts group_id="E4" subjects_affected="66" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="537"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Autoimmune haemolytic anaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" events="49" subjects_affected="43" subjects_at_risk="537"/>
                <counts group_id="E3" events="25" subjects_affected="20" subjects_at_risk="193"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E2" events="100" subjects_affected="62" subjects_at_risk="537"/>
                <counts group_id="E3" events="50" subjects_affected="28" subjects_at_risk="193"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="537"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="193"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Bicytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Coombs Negative Haemolytic Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" events="9" subjects_affected="4" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="5" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcaemia of malignancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Retinal Degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Vitreous Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Peritoneal adhesions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Neutropenic colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia Perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Large Intestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Large Intestine Perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Large Intestine Polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" events="27" subjects_affected="23" subjects_at_risk="537"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="193"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Euthanasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Catheter Site Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Bile Duct Stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Allergy to immunoglobulin therapy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Autoimmune disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Haemophagocytic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="537"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Oropharyngeal candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="127"/>
                <counts group_id="E2" events="90" subjects_affected="65" subjects_at_risk="537"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="193"/>
                <counts group_id="E4" events="18" subjects_affected="17" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Progressive multifocal leukoencephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="537"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="193"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Acute hepatitis B</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Aspergillus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Brain abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Campylobacter infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Clostridium colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cryptosporidiosis infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Encephalitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Giardiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Herpes zoster oticus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hepatitis B Reactivation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Infective exacerbation chronic obstructive airways disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="537"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="193"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Meningitis cryptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pneumonia cytomegaloviral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pneumonia pseudomonal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Splenic abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Visceral leishmaniasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>West nile viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Fungal oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cerebral toxoplasmosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Laryngitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Listeriosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Retinitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Varicella zoster virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Lung infection pseudomonal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Abdominal Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Anal Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Bacterial Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Bronchitis Viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Escherichia Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Febrile Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hepatitis E</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Legionella Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Meningitis Viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Myringitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Otitis Externa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Perineal Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pneumonia Respiratory</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pulmonary Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Streptococcal Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Tick-Borne Viral Encephalitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Vascular Device Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Radiation skin injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Radiation mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dislocation of Vertebra</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Fractured Ischium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hand Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Multiple Injuries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Post Procedural Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Post Procedural Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Skull Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Spinal Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Tumour lysis syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="537"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Steroid Diabetes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Diabetic Metabolic Decompensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Fistula inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Osteoporotic Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Psoriatic Arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Spinal Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Metastatic carcinoma of the bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Richter's syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Spinal meningioma benign</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="537"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Adenosquamous cell lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Bladder cancer stage 0, with cancer in situ</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Nasal cavity cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Primary myelofibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Metastatic bronchial carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Myelofibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Basosquamous Carcinoma of Skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Bladder Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hodgkin's Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Intraductal Papillary Mucinous Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Intraocular Melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Liver Carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Neuroendocrine Tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Peripheral T-Cell Lymphoma Unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Renal Cell Carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Squamous Cell Breast Carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Transitional Cell Carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Muscle spasticity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Chronic Inflammatory Demyelinating Polyradiculoneuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's Type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Intracranial Haemorrhagic Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Peripheral Sensorimotor Neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Posterior Reversible Encephalopathy Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hypertensive nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Urethral prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine Prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Chylothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Obliterative bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pharyngeal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pulmonary necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Respiratory alkalosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Acute Pulmonary Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="537"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="193"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Arterial Rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="503" subjects_at_risk="537"/>
                <counts group_id="E3" subjects_affected="184" subjects_at_risk="193"/>
                <counts group_id="E4" subjects_affected="107" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="19" subjects_at_risk="127"/>
                <counts group_id="E2" events="174" subjects_affected="134" subjects_at_risk="537"/>
                <counts group_id="E3" events="76" subjects_affected="50" subjects_at_risk="193"/>
                <counts group_id="E4" events="35" subjects_affected="27" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" events="119" subjects_affected="70" subjects_at_risk="537"/>
                <counts group_id="E3" events="45" subjects_affected="27" subjects_at_risk="193"/>
                <counts group_id="E4" events="12" subjects_affected="8" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="130" subjects_affected="45" subjects_at_risk="127"/>
                <counts group_id="E2" events="645" subjects_affected="288" subjects_at_risk="537"/>
                <counts group_id="E3" events="416" subjects_affected="138" subjects_at_risk="193"/>
                <counts group_id="E4" events="127" subjects_affected="58" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="34" subjects_affected="27" subjects_at_risk="127"/>
                <counts group_id="E2" events="253" subjects_affected="162" subjects_at_risk="537"/>
                <counts group_id="E3" events="116" subjects_affected="67" subjects_at_risk="193"/>
                <counts group_id="E4" events="54" subjects_affected="34" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="88" subjects_affected="53" subjects_at_risk="537"/>
                <counts group_id="E3" events="19" subjects_affected="11" subjects_at_risk="193"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E2" events="84" subjects_affected="72" subjects_at_risk="537"/>
                <counts group_id="E3" events="30" subjects_affected="24" subjects_at_risk="193"/>
                <counts group_id="E4" events="18" subjects_affected="15" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E2" events="114" subjects_affected="83" subjects_at_risk="537"/>
                <counts group_id="E3" events="44" subjects_affected="38" subjects_at_risk="193"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="27" subjects_affected="23" subjects_at_risk="127"/>
                <counts group_id="E2" events="206" subjects_affected="144" subjects_at_risk="537"/>
                <counts group_id="E3" events="147" subjects_affected="75" subjects_at_risk="193"/>
                <counts group_id="E4" events="33" subjects_affected="26" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E2" events="87" subjects_affected="68" subjects_at_risk="537"/>
                <counts group_id="E3" events="67" subjects_affected="44" subjects_at_risk="193"/>
                <counts group_id="E4" events="16" subjects_affected="15" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" events="30" subjects_affected="24" subjects_at_risk="537"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="193"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="537"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="193"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E2" events="61" subjects_affected="48" subjects_at_risk="537"/>
                <counts group_id="E3" events="42" subjects_affected="30" subjects_at_risk="193"/>
                <counts group_id="E4" events="17" subjects_affected="14" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="537"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="193"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="127"/>
                <counts group_id="E2" events="110" subjects_affected="92" subjects_at_risk="537"/>
                <counts group_id="E3" events="32" subjects_affected="30" subjects_at_risk="193"/>
                <counts group_id="E4" events="22" subjects_affected="19" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" events="85" subjects_affected="71" subjects_at_risk="537"/>
                <counts group_id="E3" events="25" subjects_affected="19" subjects_at_risk="193"/>
                <counts group_id="E4" events="27" subjects_affected="23" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="28" subjects_at_risk="127"/>
                <counts group_id="E2" events="247" subjects_affected="173" subjects_at_risk="537"/>
                <counts group_id="E3" events="93" subjects_affected="61" subjects_at_risk="193"/>
                <counts group_id="E4" events="39" subjects_affected="28" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" events="37" subjects_affected="31" subjects_at_risk="537"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="193"/>
                <counts group_id="E4" events="15" subjects_affected="9" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="127"/>
                <counts group_id="E2" events="43" subjects_affected="39" subjects_at_risk="537"/>
                <counts group_id="E3" events="23" subjects_affected="18" subjects_at_risk="193"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="537"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="193"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E2" events="28" subjects_affected="25" subjects_at_risk="537"/>
                <counts group_id="E3" events="24" subjects_affected="19" subjects_at_risk="193"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E2" events="62" subjects_affected="48" subjects_at_risk="537"/>
                <counts group_id="E3" events="17" subjects_affected="14" subjects_at_risk="193"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E2" events="35" subjects_affected="29" subjects_at_risk="537"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="193"/>
                <counts group_id="E4" events="16" subjects_affected="11" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="537"/>
                <counts group_id="E3" events="19" subjects_affected="14" subjects_at_risk="193"/>
                <counts group_id="E4" events="8" subjects_affected="5" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" events="19" subjects_affected="12" subjects_at_risk="537"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="193"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" events="33" subjects_affected="28" subjects_at_risk="537"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="193"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="537"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="193"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="537"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="193"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" events="45" subjects_affected="44" subjects_at_risk="537"/>
                <counts group_id="E3" events="15" subjects_affected="11" subjects_at_risk="193"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="36" subjects_affected="33" subjects_at_risk="537"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="193"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="537"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="193"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" events="37" subjects_affected="35" subjects_at_risk="537"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="193"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="18" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E2" events="57" subjects_affected="46" subjects_at_risk="537"/>
                <counts group_id="E3" events="25" subjects_affected="23" subjects_at_risk="193"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="537"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="537"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="193"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="127"/>
                <counts group_id="E2" events="70" subjects_affected="57" subjects_at_risk="537"/>
                <counts group_id="E3" events="33" subjects_affected="28" subjects_at_risk="193"/>
                <counts group_id="E4" events="18" subjects_affected="17" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E2" events="66" subjects_affected="53" subjects_at_risk="537"/>
                <counts group_id="E3" events="24" subjects_affected="24" subjects_at_risk="193"/>
                <counts group_id="E4" events="13" subjects_affected="11" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="537"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="193"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" events="30" subjects_affected="25" subjects_at_risk="537"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="193"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" events="63" subjects_affected="46" subjects_at_risk="537"/>
                <counts group_id="E3" events="31" subjects_affected="24" subjects_at_risk="193"/>
                <counts group_id="E4" events="15" subjects_affected="11" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" events="51" subjects_affected="44" subjects_at_risk="537"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="193"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E2" events="61" subjects_affected="53" subjects_at_risk="537"/>
                <counts group_id="E3" events="20" subjects_affected="17" subjects_at_risk="193"/>
                <counts group_id="E4" events="18" subjects_affected="16" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800 821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

